ReviewFuture oncology (London, England)2012
Bevacizumab and breast cancer: what does the future hold?
Review in Future oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.Annals of surgical oncology · 2017Trial
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.The Lancet. Oncology · 2015Trial
- Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.Medical science monitor : international medical journal of experimental and clinical research · 2014Trial
- The discovery of Bevacizumab. An historical reappraisal.Clinical and experimental medicine · 2025Review
- Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.World journal of oncology · 2025Review
- An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.Molecular oncology · 2024Article
- Review
- Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.Science translational medicine · 2023Article
- Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).Breast care (Basel, Switzerland) · 2021Article
- Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer.International journal of molecular sciences · 2020Article
- Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.Breast cancer : basic and clinical research · 2020Review
- Intravital microscopy in the study of the tumor microenvironment: from bench to human application.Oncotarget · 2018Review
- Angiopoietin pathway gene expression associated with poor breast cancer survival.Breast cancer research and treatment · 2017Article
- Article
- Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.Oncotarget · 2016Article
- Article
- A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.BMC cancer · 2015Article
- Molecularly targeted drugs for metastatic colorectal cancer.Drug design, development and therapy · 2013Review
- Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.Journal of mammary gland biology and neoplasia · 2012Review
- New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis.Pulmonary circulation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer is a major health concern for many women, but despite the current standard therapies, many women still die of metastatic disease. Angiogenesis has been evaluated as a possible target for therapy and bevacizumab (Avastin(®), Genentech/Roche, CA, USA), a monoclonal antibody against VEGF-A, has been developed to target this. Current clinical trials utilizing bevacizumab have shown an increase in progression-free survival, but this has not translated to an increase in overall survival in breast cancer patients. In this article, we summarize the currently published trials utilizing bevacizumab in the treatment of breast cancer and describe various methods of measuring angiogenesis in vitro and in vivo. We also describe the related process of lymphangiogenesis, as this may contribute to the mechanism of cancer progression and may be a potential target for therapy in the future. Understanding these processes may help us develop new treatments for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.